Janux Therapeutics, INC Form 4 insider transactions

Avalon Ventures XI, L.P. reports multiple transactions involving Janux Therapeutics, Inc. common stock and stock options, including sales at $42 and option exercises at various prices.

Eric Dobmeier, a director at Janux Therapeutics, filed an amended Form 4 to correct the number of Restricted Stock Units (RSUs) and stock options granted on July 19, 2024.

Natasha Hernday, a director at Janux Therapeutics, filed an amended Form 4 to correct the number of RSUs and shares subject to a stock option granted on July 19, 2024.

Director Eric Dobmeier received stock options and restricted stock units from Janux Therapeutics, according to a Form 4 filing.

Natasha Hernday, a director at Janux Therapeutics, received stock options and restricted stock units (RSUs) on July 19, 2024, as reported in a Form 4 filing with the SEC.

RA Capital Management and related entities report acquisition of restricted stock units and stock options in Janux Therapeutics, along with adjustments to their beneficial ownership.

Director Jay Lichter reports acquiring shares and stock options in Janux Therapeutics, Inc.

Director Alana B. McNulty receives stock options and restricted stock units in Janux Therapeutics, Inc.

Director Winston Kung of Janux Therapeutics received stock options and restricted stock units on June 26, 2024, according to a Form 4 filing with the SEC.

Director Sheila Gujrathi reports acquisition of 2,500 shares of common stock and 8,350 stock options in Janux Therapeutics.

Director Ronald W. Barrett acquired 2,500 shares of common stock and options for 8,350 shares in Janux Therapeutics, Inc.

Director Simson Jake received stock options and restricted stock units from Janux Therapeutics, but disclaims beneficial ownership due to an arrangement with RA Capital Management.

Director Vickie L Capps acquired stock options and restricted stock units in Janux Therapeutics, Inc.

Director Jay Lichter reports selling Janux Therapeutics (JANX) shares held directly and indirectly through affiliated investment partnerships.

Tighe Reardon, Acting Chief Financial Officer of Janux Therapeutics, reports the sale of common stock held indirectly through Avalon BioVentures.

Avalon Ventures XI, L.P. reports the sale of Janux Therapeutics, Inc. shares across multiple transactions on June 3, 2024.

RA Capital Management and related entities acquired pre-funded warrants for Janux Therapeutics, Inc. potentially increasing their ownership stake.

Avalon Ventures XI, L.P. reports an in-kind distribution of Janux Therapeutics shares to its partners, resulting in changes in beneficial ownership.

Director Sheila Gujrathi reports a pro rata, in-kind distribution of Janux Therapeutics common stock.

Director Vickie L Capps reports acquiring 1,493 shares of Janux Therapeutics through an in-kind distribution on February 29, 2024.